

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

## Nexlizet (bempedoic acid/ezetimibe)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Nexlizet (bempedoic acid/ezetimibe)	May be subject to quantity limit

### APPROVAL CRITERIA

Initial requests for Nexlizet (bempedoic acid/ezetimibe) may be approved when the following criteria are met:

- I. Individual is at high risk for atherosclerotic cardiovascular disease (ASCVD) events as identified by one of the following:
  - A. Individual has Heterozygous Familial Hypercholesterolemia (HeFH) confirmed by (Singh 2015; WHO 1999):
    1. Presence of a mutation in LDLR, ApoB, PCSK9 or ARH adaptor protein (LDLRAP1) gene; **OR**
    2. WHO/Dutch Lipid Clinic Network criteria with score of greater than eight points;
  - OR**
  - B. Individual has a history of clinical atherosclerotic cardiovascular disease (ASCVD), including **one or more** of the following (AHA/ACC 2018):
    1. Acute coronary syndrome;
    2. Coronary artery disease (CAD);
    3. History of myocardial infarction (MI);
    4. Stable or unstable angina;
    5. Coronary or other arterial revascularization;
    6. Stroke;
    7. Transient ischemic attack (TIA);
    8. Peripheral arterial disease (PAD);

### **AND**

- II. Individual meets one of the following:
  - A. Individual is on concomitant statin therapy at the maximum tolerated dose; **OR**
  - B. Individual is statin intolerant based on one of the following:
    1. Inability to tolerate at least two statins, with at least one started at the lowest starting daily dose, demonstrated by intolerable

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

- symptoms or clinically significant biomarker changes (NLA 2014); **OR**
2. Statin associated rhabdomyolysis after a trial of one statin;

**OR**

- C. Individual has a contraindication for statin therapy including active liver disease, unexplained persistent elevation of hepatic transaminases or pregnancy;

**AND**

- III. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of ezetimibe therapy and was unable to meet LDL-C goal (AHA/ACC 2018);

**AND**

- IV. Individual has achieved suboptimal lipid lowering response to lipid lowering therapy and lifestyle modifications as defined (AHA/ACC 2018):
  - A. For individuals where initial LDL-C is known:
    1. Less than 50% reduction in LDL-C;

**OR**

- B. For individuals where initial LDL-C is unknown:
  1. ASCVD and LDL-C remains greater than or equal to 70 mg/dL; **OR**
  2. No history of ASCVD and LDL-C remains greater than or equal to 100 mg/dL.

Continuation requests for Nexlizet (bempedoic acid/ezetimibe) may be approved when the following criteria are met:

- I. Individual continues to receive concomitant maximally tolerated statin therapy (unless contraindicated or not tolerated); **AND**
- II. Confirmation of LDL reduction has been provided.

Nexlizet (bempedoic acid/ezetimibe) may not be approved for the following:

- I. Individual with moderate to severe hepatic impairment (Child-Pugh B or C).

**Key References:**

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

1. Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. *Atherosclerosis*. 2018;277:195-203.
2. Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. *Eur J Prev Cardiol*. 2019:2047487319864671. [Epub ahead of print]
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: February 27, 2020.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. *JAMA*. 2019;322(18):1780-1788.
6. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. *J Am Coll Cardiol*. 2018. <https://doi.org/10.1016/j.jacc.2018.11.003>.
7. Guyton JR, Bays HE, Grundy SM, Jacobson TA. The National Lipid Association (NLA) Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. *J Clin Lipidol*. 2014;8(3 Suppl):S72–81.
8. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology (AAACE) guidelines for management of dyslipidemia and prevention of cardiovascular disease. *Endocr Pract*. 2017;23(Suppl 2):1-87.
9. Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. *J Am Heart Assoc*. 2019;8(7):e011662.
10. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
11. Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. *N Engl J Med*. 2019;380(11):1022-1032.
12. Singh S, Bittner V. Familial hypercholesterolemia--epidemiology, diagnosis, and screening. *Curr Atheroscler Rep*. 2015; 17(2):482.
13. World Health Organization. Familial hypercholesterolemia—report of a second WHO Consultation. Geneva, Switzerland: World Health Organization, 1999. Available at: [http://whqlibdoc.who.int/hq/1999/WHO\\_HGN\\_FH\\_CONS\\_99.2.pdf?ua=1](http://whqlibdoc.who.int/hq/1999/WHO_HGN_FH_CONS_99.2.pdf?ua=1). Accessed: July 11, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.